Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics
Strategic Profile
Lead product candidates include Tamibarotene, a selective retinoic acid receptor alpha agonist in Phase III clinical trial for myelodysplastic syndrome and Phase II for acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I clinical trial. The company is navigating significant development challenges following recent clinical trial setbacks.
Cyborg Score Rationale
The Phase 3 SELECT-MDS-1 trial of tamibarotene failed to achieve its primary endpoint of complete response rate. Syros plans to voluntarily delist its common stock from Nasdaq and deregister to terminate its reporting obligations under the Exchange Act. The company faces existential challenges with minimal revenue and substantial operating losses.
Top Insights
Phase 3 SELECT-MDS-1 trial of tamibarotene failed to achieve primary endpoint - major setback for lead program
Company plans voluntary delisting from Nasdaq and deregistration - signals reduced transparency and financial stress
Leverages proprietary gene control platform to design therapies for cancer and monogenic diseases - differentiated technology approach
Rege Nephro acquired Tamibarotene-related clinical and non-clinical assets from Syros through mutual agreement - recent asset divestiture
Named Competitors
Oncology Programs — Established cancer therapeutic portfolio
Hematologic Malignancy Treatments — Market leader in multiple myeloma and related conditions
Gene-Targeted Therapeutics — Gene control and editing platform company
Recent Developments
(2024) SELECT-MDS-1 Phase 3 trial failure - Tamibarotene did not meet primary endpoint
(2024) Announced planned voluntary delisting from Nasdaq
(2024) Asset sale - Tamibarotene assets transferred to Rege Nephro
(2024) Multiple shareholder litigation investigations announced
Open the full interactive Syros Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.